China SXT Pharmaceuticals annual return on equity
2018
2019
2020
2021
2022
2023
2024
2025
2026
China SXT Pharmaceuticals Return on Equity (ROE) Growth & History (SXTC)
China SXT Pharmaceuticals's return on equity was −27.49% for fiscal 2026.
View full China SXT Pharmaceuticals company overviewChina SXT Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-03-31 | −27.49% | −4.99 pp |
| 2025 | 2025-03-31 | −22.50% | −0.85 pp |
| 2024 | 2024-03-31 | −21.65% | +16.92 pp |
| 2023 | 2023-03-31 | −38.57% | −2.77 pp |
| 2022 | 2022-03-31 | −35.80% | −14.13 pp |
| 2021 | 2021-03-31 | −21.67% | +78.65 pp |
| 2020 | 2020-03-31 | −100.32% | −121.71 pp |
| 2019 | 2019-03-31 | 21.39% | −24.84 pp |
| 2018 | 2018-03-31 | 46.22% | — |
China SXT Pharmaceuticals return on equity trends
Over the last five fiscal years, China SXT Pharmaceuticals's return on equity decreased from −21.67% to −27.49%, a change of −5.82 percentage points.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review China SXT Pharmaceuticals source filings ↗